TorreyPines Therapeutics Completes Phase I Clinical Trial For Tezampanel (NGX424), A First-in-Class Compound For Acute Migraine

Tue, 16 May 2006 11:00 AM EST

... TorreyPines Therapeutics, Inc. todayannounced the completion of a Phase I clinical trial for tezampanel(NGX424), a first-in-class compound in development for the treatment ofacute migraine, and plans to move forward with a Phase II clinical trialduring the second half of this year. [click link for full article] ...